Department of Neonatology, Women's Hospital of Jiangnan University, Wuxi Maternity and Child Health Care Hospital, Wuxi, China.
Wuxi Children's Hospital, Children's Hospital of Jiangnan University, Wuxi, China.
Front Cell Infect Microbiol. 2023 Aug 18;13:1254198. doi: 10.3389/fcimb.2023.1254198. eCollection 2023.
OBJECTIVES: Digestive system diseases have evolved into a growing global burden without sufficient therapeutic measures. () is considered as a new potential economical therapy for its probiotic effects in the gastrointestinal system. We have provided an overview of the researches supporting various strains' application in treating common digestive system diseases, including infantile colic, diarrhea, constipation, functional abdominal pain, infection, inflammatory bowel disease, diverticulitis, colorectal cancer and liver diseases. METHODS: The summarized literature in this review was derived from databases including PubMed, Web of Science, and Google Scholar. RESULTS: The therapeutic effects of in digestive system diseases may depend on various direct and indirect mechanisms, including metabolite production as well as modulation of the intestinal microbiome, preservation of the gut barrier function, and regulation of the host immune system. These actions are largely strain-specific and depend on the activation or inhibition of various certain signal pathways. It is well evidenced that can be effective both as a prophylactic measure and as a preferred therapy for infantile colic, and it can also be recommended as an adjuvant strategy to diarrhea, constipation, infection in therapeutic settings. While preclinical studies have shown the probiotic potential of in the management of functional abdominal pain, inflammatory bowel disease, diverticulitis, colorectal cancer and liver diseases, its application in these disease settings still needs further study. CONCLUSION: This review focuses on the probiotic effects of on gut homeostasis via certain signaling pathways, and emphasizes the importance of these probiotics as a prospective treatment against several digestive system diseases.
目的:消化系统疾病在缺乏足够治疗措施的情况下,已演变成全球日益严重的负担。()因其在胃肠道中的益生菌作用而被认为是一种新的潜在经济治疗方法。我们概述了支持各种菌株应用于治疗常见消化系统疾病的研究,包括婴儿绞痛、腹泻、便秘、功能性腹痛、感染、炎症性肠病、憩室炎、结直肠癌和肝病。
方法:本综述中总结的文献来自包括 PubMed、Web of Science 和 Google Scholar 在内的数据库。
结果:在消化系统疾病中,()的治疗效果可能取决于各种直接和间接的机制,包括代谢产物的产生以及肠道微生物组的调节、肠道屏障功能的维持和宿主免疫系统的调节。这些作用在很大程度上是菌株特异性的,取决于各种特定信号通路的激活或抑制。有充分的证据表明,()既可以作为预防措施,也可以作为婴儿绞痛的首选治疗方法,也可以作为治疗腹泻、便秘、感染的辅助策略。虽然临床前研究表明()在功能性腹痛、炎症性肠病、憩室炎、结直肠癌和肝病的管理中有益生菌潜力,但在这些疾病中的应用仍需要进一步研究。
结论:本综述重点介绍了()通过特定信号通路对肠道内稳态的益生菌作用,并强调了这些益生菌作为几种消化系统疾病潜在治疗方法的重要性。
Front Cell Infect Microbiol. 2023
Medicina (Kaunas). 2021-6-23
Adv Exp Med Biol. 2019
Medicina (Kaunas). 2021-8-5
Benef Microbes. 2022-8-3
Nutrients. 2018-11-29
Am J Transl Res. 2025-6-15
Probiotics Antimicrob Proteins. 2025-4-26
Evol Appl. 2025-4-23
Int J Mol Sci. 2023-6-9
Probiotics Antimicrob Proteins. 2023-8